Hepatoprotective effects of silymarin in management of liver injury caused by tuberculosis treatment
Tuberculosis (TB) is a chronic infection of global-health concern because of its high incidence, costly medical treatment, drug resistance and risk of co-infections. Anti-TB treatment involves a combination of drugs with high degree of liver toxicity, leading to drug-induced liver injury in 2-28% of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
BioExcel Publishing Ltd,
2023-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_8a02fad3a97e4bdea241e4b07fbc1c3d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yeong Yeh Lee |e author |
| 700 | 1 | 0 | |a Vincent Tee |e author |
| 245 | 0 | 0 | |a Hepatoprotective effects of silymarin in management of liver injury caused by tuberculosis treatment |
| 260 | |b BioExcel Publishing Ltd, |c 2023-01-01T00:00:00Z. | ||
| 500 | |a 10.7573/dic.2023-2-11 | ||
| 500 | |a 1740-4398 | ||
| 520 | |a Tuberculosis (TB) is a chronic infection of global-health concern because of its high incidence, costly medical treatment, drug resistance and risk of co-infections. Anti-TB treatment involves a combination of drugs with high degree of liver toxicity, leading to drug-induced liver injury in 2-28% of patients who receive anti-TB treatment. In this case report, a patient with TB experienced drug-induced liver injury, and the initiation of treatment with silymarin 140 mg three-times daily resulted in a significant hepatoprotective effects as shown by the decreased liver enzyme activity. This article is part of the Current clinical use of silymarin in the treatment of toxic liver diseases: a case series Special Issue: https://www.drugsincontext.com/special_issues/ current-clinical-use-of-silymarin-in-the-treatmentof- toxic-liver-diseases-a-case-series | ||
| 546 | |a EN | ||
| 690 | |a case report | ||
| 690 | |a deranged liver enzymes | ||
| 690 | |a druginduced liver injury | ||
| 690 | |a fatty liver disease | ||
| 690 | |a silymarin | ||
| 690 | |a tuberculosis treatment | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drugs in Context, Iss 12, Pp 1-5 (2023) | |
| 787 | 0 | |n https://www.drugsincontext.com/hepatoprotective-effects-of-silymarin-in-management-of-liver-injury-caused-by-tuberculosis-treatment | |
| 787 | 0 | |n https://doaj.org/toc/1740-4398 | |
| 856 | 4 | 1 | |u https://doaj.org/article/8a02fad3a97e4bdea241e4b07fbc1c3d |z Connect to this object online. |